Overexpression of hypoxia inducible factor-1 alpha is an independent risk factor for recurrence after curative resection of colorectal liver metastases

Annals of Surgical Oncology

Volumn 20, Issue 3 SUPPL., 2013, Pages

  Shimomura, Manabu ^a   Hinoi, Takao ^a   Kuroda, Shintaro ^a   Adachi, Tomohiro ^a   Kawaguchi, Yasuo ^a   Sasada, Tatsunari ^a   Takakura, Yuji ^a   Egi, Hiroyuki ^a   Okajima, Masazumi ^a   Tashiro, Hirotaka ^a   Nishizaka, Takashi ^b   Ohdan, Hideki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; K RAS PROTEIN; OXALIPLATIN; PROTEIN P53; UFT; VASCULOTROPIN; HIF1A PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; COLON RESECTION; COLORECTAL LIVER METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATION; PRIMARY TUMOR; PROTEIN EXPRESSION; RISK FACTOR; YOUNG ADULT; CANCER STAGING; COLORECTAL NEOPLASMS; FOLLOW UP; GENETICS; LIVER NEOPLASMS; METABOLISM; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84892795890     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-2945-2     Document Type: Article

References (33)

1. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94:982-999.
2. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759-766.
3. Assumpcao L, Choti MA, Gleisner AL, et al. Patterns of recurrence following liver resection for colorectal metastases: effect of primary rectal tumor site. Arch Surg. 2008;143:743-749.
4. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721-732.
5. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 2010;29:625-634.
6. Rasheed S, Harris AL, Tekkis PP, et al. Hypoxia-inducible factor- 1alpha and -2 alpha are expressed in most rectal cancers but only hypoxia-inducible factor-1 alpha is associated with prognosis. Br J Cancer. 2009;100:1666-1673.
7. Baba Y, Nosho K, Shima K, et al. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol. 2010;176:2292-2301.
8. Kuwai T, Kitadai Y, Tanaka S, et al. Expression of hypoxiainducible factor-1 alpha is associated with tumor vascularization in human colorectal carcinoma. Int J Cancer. 2003;105:176-181.
9. Yoshimura H, Dhar DK, Kohno H, et al. Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase- 2 expression. Clin Cancer Res. 2004;10:8554-8560.
10. Cao D, Hou M, Guan YS, et al. Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC Cancer. 2009;9:432.
11. Imamura T, Kikuchi H, Herraiz MT, et al. HIF-1alpha and HIF- 2alpha have divergent roles in colon cancer. Int J Cancer. 2009;124:763-771.
12. Mizukami Y, Jo WS, Duerr EM, et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med. 2005;11:992-997.
13. Frede S, Freitag P, Otto T, et al. The proinflammatory cytokine interleukin 1beta and hypoxia cooperatively induce the expression of adrenomedullin in ovarian carcinoma cells through hypoxia inducible factor 1 activation. Cancer Res. 2005;65: 4690-4697.
14. Karhausen J, Haase VH, Colgan SP. Inflammatory hypoxia: role of hypoxia-inducible factor. Cell Cycle. 2005;4:256-258.
15. van der Bilt JD, Soeters ME, Duyverman AM, et al. Perinecrotic hypoxia contributes to ischemia/reperfusion-accelerated outgrowth of colorectal micrometastases. Am J Pathol. 2007;170: 1379-1388.
16. Moeller BJ, Cao Y, Li CY, et al. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell. 2004;5: 429-441.
17. Bardos JI, Ashcroft M. Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays. 2004;26:262-269.
18. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 2000;14:34-44.
19. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361: 2449-2460.
20. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240: 205-213.
21. Ikeda S, Shimizu Y, Fujimori M, et al. Immunohistochemical and mutational analyses of beta-catenin, Ki-ras, and p53 in two subtypes of colorectal mucinous carcinoma. Clin Cancer Res. 2003;9:5660-5665.
22. Loupakis F, Pollina L, Stasi I, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol. 2009;27:2622-2629.
23. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999;59:5830-5835.
24. Birner P, Schindl M, Obermair A, et al. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 2000;60:4693-4696.
25. Schindl M, Schoppmann SF, Samonigg H, et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res. 2002;8:1831-1837.
26. Sullivan R, Pare GC, Frederiksen LJ, et al. Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther. 2008;7:1961-1973.
27. Guba M, Seeliger H, Kleespies A, et al. Vascular endothelial growth factor in colorectal cancer. Int J Colorectal Dis. 2004;19:510-517.
28. Kwon HC, Kim SH, Oh SY, et al. Clinicopathological significance of p53, hypoxia-inducible factor 1alpha, and vascular endothelial growth factor expression in colorectal cancer. Anticancer Res. 2010;30:4163-4168.
29. Kwon HC, Kim SH, Oh SY, et al. Clinicopathological significance of nuclear factor-kappa B, HIF-1 alpha, and vascular endothelial growth factor expression in stage III colorectal cancer. Cancer Sci. 2010;101:1557-1561.
30. Kikuchi H, Pino MS, Zeng M, et al. Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1 alpha and -2 alpha in colon cancer. Cancer Res. 2009;69:8499-8506.
31. Simiantonaki N, Taxeidis M, Jayasinghe C, et al. Hypoxiainducible factor 1 alpha expression increases during colorectal carcinogenesis and tumor progression. BMC Cancer. 2008;8:320.
32. Kuramochi H, Hayashi K, Uchida K, et al. Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res. 2006;12:29-33.
33. Chen J, Li Q, Wang C, et al. Prognostic significance of c-erbB-2 and vascular endothelial growth factor in colorectal liver metastases. Ann Surg Oncol. 2010;17:1555-1563.